Heron Therapeutics

Redwood City, United States Founded: 1983 • Age: 43 yrs
Reformulated injectables for chemotherapy side effects and pain are developed.
Request Access

About Heron Therapeutics

Heron Therapeutics is a company based in Redwood City (United States) founded in 1983. It operates as a Direct-to-Consumer (D2C). Heron Therapeutics has raised $32.14 million across 10 funding rounds from investors including Hercules Capital, Rubric Capital and Velan Capital. The company has 122 employees as of December 31, 2024. Heron Therapeutics offers products and services including SUSTOL, CINVANTI, ZYNRELEF, and APONVIE. Heron Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.

  • Headquarter Redwood City, United States
  • Employees 122 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Heron Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $144.28 M
    13.57
    as on Dec 31, 2024
  • Net Profit
    $-13.58 M
    87.72
    as on Dec 31, 2024
  • EBITDA
    $-9.04 M
    91.61
    as on Dec 31, 2024
  • Total Equity Funding
    $32.14 M (USD)

    in 10 rounds

  • Latest Funding Round
    $30 M (USD), Post-IPO

    Jul 24, 2023

  • Investors
  • Employee Count
    122

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Heron Therapeutics

Heron Therapeutics is a publicly listed company on the NASDAQ with ticker symbol HRTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: HRTX . Sector: Health technology · USA

Products & Services of Heron Therapeutics

Heron Therapeutics offers a comprehensive portfolio of products and services, including SUSTOL, CINVANTI, ZYNRELEF, and APONVIE. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Used for preventing chemotherapy-induced nausea and vomiting.

Administered to prevent nausea and vomiting from chemotherapy.

Designed for managing postoperative pain in patients.

Utilized for preventing postoperative nausea and vomiting.

People of Heron Therapeutics
Headcount 200-500
Employee Profiles 82
Board Members and Advisors 5
Employee Profiles
People
John Arthur
Vice President Manufacturing And Supply
People
Adriane Morris
Director, Human Resources
People
Ira Duarte
EVP & CFO
People
Ana Ochoa
Device And Packaging Engineer

Unlock access to complete

Board Members and Advisors
people
Craig Johnson
Lead Independent Director
people
Adam Morgan
Chairman

Unlock access to complete

Funding Insights of Heron Therapeutics

Heron Therapeutics has successfully raised a total of $32.14M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 10
  • Last Round Post-IPO — $30.0M
  • First Round

    (04 Nov 2009)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2023 Amount Post-IPO - Heron Therapeutics Valuation

investors

Aug, 2022 Amount Post-IPO - Heron Therapeutics Valuation

investors

May, 2021 Amount Post-IPO - Heron Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Heron Therapeutics

Heron Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Hercules Capital, Rubric Capital and Velan Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Clearline Capital, LLC is engaged in emerging market debt solutions.
Founded Year Domain Location
Venture debt financing is provided to companies in multiple sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Heron Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Heron Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Heron Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Heron Therapeutics

Heron Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Heron Therapeutics

Frequently Asked Questions about Heron Therapeutics

When was Heron Therapeutics founded?

Heron Therapeutics was founded in 1983 and raised its 1st funding round 26 years after it was founded.

Where is Heron Therapeutics located?

Heron Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.

Is Heron Therapeutics a funded company?

Heron Therapeutics is a funded company, having raised a total of $32.14M across 10 funding rounds to date. The company's 1st funding round was a Post-IPO of $150M, raised on Nov 04, 2009.

How many employees does Heron Therapeutics have?

As of Dec 31, 2024, the latest employee count at Heron Therapeutics is 122.

What is the annual revenue of Heron Therapeutics?

Annual revenue of Heron Therapeutics is $144.28M as on Dec 31, 2024.

What does Heron Therapeutics do?

Heron Therapeutics is dedicated to advancing therapeutic standards for patients through innovative science and technologies. The company is engaged in developing and commercializing a portfolio of best-in-class therapies aimed at addressing unmet medical needs in acute care and oncology sectors. Solutions such as SUSTOL, CINVANTI, ZYNRELEF, and APONVIE are provided to prevent issues like chemotherapy-induced nausea, vomiting, and postoperative pain. The focus is placed on improving patient outcomes by rethinking treatment approaches and reducing reliance on opioids in surgical settings.

Who are the top competitors of Heron Therapeutics?

Heron Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does Heron Therapeutics offer?

Heron Therapeutics offers SUSTOL, CINVANTI, ZYNRELEF, and APONVIE.

Is Heron Therapeutics publicly traded?

Yes, Heron Therapeutics is publicly traded on NASDAQ under the ticker symbol HRTX.

Who are Heron Therapeutics's investors?

Heron Therapeutics has 7 investors. Key investors include Hercules Capital, Rubric Capital, Velan Capital, Clearline Capital, and Deep Track Capital.

What is Heron Therapeutics's ticker symbol?

The ticker symbol of Heron Therapeutics is HRTX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available